Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RNA-based therapeutics: an overview and prospectus
Cell Death & Disease Open Access 23 July 2022
-
Noncoding RNAs regulate alternative splicing in Cancer
Journal of Experimental & Clinical Cancer Research Open Access 06 January 2021
-
Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting
Signal Transduction and Targeted Therapy Open Access 06 November 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Small molecules against RNA targets attract big backers. Nat Rev Drug Discov 16, 813–815 (2017). https://doi.org/10.1038/nrd.2017.239
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.239
This article is cited by
-
RNA-based therapeutics: an overview and prospectus
Cell Death & Disease (2022)
-
Noncoding RNAs regulate alternative splicing in Cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting
Signal Transduction and Targeted Therapy (2020)
